Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia

BACKGROUND: LY3202626 is a small molecule inhibitor of β-site amyloid precursor protein cleaving enzyme (BACE)1 shown to reduce amyloid-β (Aβ)(1–40) and Aβ(1–42) concentrations in plasma and cerebrospinal fluid developed for the treatment of Alzheimer’s disease (AD). OBJECTIVE: To assess the change...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Albert C., Evans, Cynthia Duggan, Mancini, Michele, Wang, Hong, Shcherbinin, Sergey, Lu, Ming, Natanegara, Fanni, Willis, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150257/
https://www.ncbi.nlm.nih.gov/pubmed/34113788
http://dx.doi.org/10.3233/ADR-210296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150257/
https://www.ncbi.nlm.nih.gov/pubmed/34113788
http://dx.doi.org/10.3233/ADR-210296

Ejemplares similares